294 related articles for article (PubMed ID: 35609569)
1. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
2. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma.
Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW
J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032
[TBL] [Abstract][Full Text] [Related]
3. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
[TBL] [Abstract][Full Text] [Related]
4. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
[TBL] [Abstract][Full Text] [Related]
5. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
[No Abstract] [Full Text] [Related]
6. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
7. New insights into the Immune TME of adult-type diffuse gliomas.
Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
9. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
10. Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
Ludwig N; Rao A; Sandlesh P; Yerneni SS; Swain AD; Bullock KM; Hansen KM; Zhang X; Jaman E; Allen J; Krueger K; Hong CS; Banks WA; Whiteside TL; Amankulor NM
Neuro Oncol; 2022 Feb; 24(2):197-209. PubMed ID: 34254643
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
12. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
13. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma.
Dettling S; Stamova S; Warta R; Schnölzer M; Rapp C; Rathinasamy A; Reuss D; Pocha K; Roesch S; Jungk C; Warnken U; Eckstein V; Grabe N; Schramm C; Weigand MA; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
Clin Cancer Res; 2018 Jun; 24(12):2951-2962. PubMed ID: 29563135
[No Abstract] [Full Text] [Related]
14. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
15. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK
Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
17. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.
Friedrich M; Sankowski R; Bunse L; Kilian M; Green E; Ramallo Guevara C; Pusch S; Poschet G; Sanghvi K; Hahn M; Bunse T; Münch P; Gegner HM; Sonner JK; von Landenberg A; Cichon F; Aslan K; Trobisch T; Schirmer L; Abu-Sammour D; Kessler T; Ratliff M; Schrimpf D; Sahm F; Hopf C; Heiland DH; Schnell O; Beck J; Böttcher C; Fernandez-Zapata C; Priller J; Heiland S; Gutcher I; Quintana FJ; von Deimling A; Wick W; Prinz M; Platten M
Nat Cancer; 2021 Jul; 2(7):723-740. PubMed ID: 35121943
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
20. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
